Biosimilar substitution in France: no way back?
Beginning on 1 January 2014, French pharmacists are now legally permitted to substitute a biosimilar for the prescribed (reference) biological medicine as long as the prescribing physician has not marked the prescription as ‘non-substitutable’.
According to the new law, substitution is allowed only when initiating a course of treatment and if the biosimilar belongs to the same group as the prescribed product, known as a ‘similar biologic group’. These groups will be drawn up by French healthcare authority ANSM.
However, as (i) the criteria for inclusion in a ‘similar biologic group’ by the ANSM, (ii) the procedure for registration on the biosimilar register (entitled ‘list of reference of similar biologic groups’) and the content of that list and (iii) the precise conditions for biosimilar substitution by a pharmacist remain to be further defined in decrees from the Administrative Supreme Court, biosimilar substitution should only occur in practice after these decrees have been adopted…
If you are registered and logged in to the site, click on the link below to read the rest of the Allen & Overy briefing. If not, please register or sign in with your details below.
News from Allen & Overy
News from The Lawyer
Briefings from Allen & Overy
Asset managers continue to face significant regulatory challenges and 2014 marks the first full year of operation for many new regulations.
Barack Obama has signed an executive order authorising targeted sanctions against individuals determined to be connected with the ongoing situation in Ukraine.
Analysis from The Lawyer
Imagine you’re the general counsel of London-based private equity investor BC Partners. You’re sipping on your coffee, hashing out the details of your imminent £382m investment into UK-based business publishing company Mergermarket.
‘Exotic’ investors and opportunities for legal work beyond M&A feature in The Lawyer’s high-level roundtable debate on south-east Europe